The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qian, Y.
Right arrow Articles by Clarke, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qian, Y.
Right arrow Articles by Clarke, S. H.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
Medline Plus Health Information
*Lupus
The Journal of Immunology, 2001, 166: 2412-2419.
Copyright © 2001 by The American Association of Immunologists

Lupus-Specific Antiribonucleoprotein B Cell Tolerance in Nonautoimmune Mice Is Maintained by Differentiation to B-1 and Governed by B Cell Receptor Signaling Thresholds1

Ye Qian*, Carlos Santiago{dagger}, Michelle Borrero*, Thomas F. Tedder{ddagger} and Stephen H. Clarke2,*

* Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599; {dagger} Department of Biology, University of Puerto Rico, Rio Piedras, Puerto Rico; and {ddagger} Department of Immunology, Duke University, Durham, NC 27710


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Systemic lupus erythematosus is an autoimmune disease characterized by the presence of autoantibodies. One of the unique targets of the immune system in systemic lupus erythematosus is Sm, a ribonucleoprotein present in all cells. To understand the regulation of B cells specific to the Sm Ag in normal mice, we have generated an Ig H chain transgenic mouse (2-12H Tg). 2-12H Tg mice produce B cells specific for the Sm that remain tolerant due to ignorance. We demonstrate here that anti-Sm B cells of 2-12H Tg mice can differentiate into Sm-specific peritoneal B-1 cells that remain tolerant. Differentiation to B-1 and tolerance are governed by the strength of B cell receptor signaling, since manipulations of the B cell receptor coreceptors CD19 and CD22 affect anti-Sm B cell differentiation and autoantibody production. These results suggest a differentiation scheme in which peripheral ignorance to Sm is maintained in mice by the differentiation of anti-Sm B cells to B-1 cells that have increased activation thresholds.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Systemic lupus erythematosus is an autoimmune disease characterized by the production of Abs against a variety of self-Ags, including IgG (rheumatoid factor), ssDNA, dsDNA, and ribonucleoproteins (RNPs)3 (1). In addition to autoantibody production, B cells participate in the disease process by serving as APCs (2). Thus, understanding how autoreactive cells are normally regulated is of great interest. Ig transgenic (Tg) mice have been used to explore the mechanisms that regulate B cells specific for autoantigens targeted in lupus, most notably those specific for DNA and IgG (3, 4, 5). These studies indicate that clonal deletion, receptor editing, anergy, follicular exclusion, and ignorance all play roles in the regulation of B cells specific for Ags targeted in lupus (3, 4, 5, 6, 7, 8, 9, 10).

B-1 cells in normal mice are frequently autoreactive and include cells specific for the lupus Ags DNA and IgG (11, 12). B-1 cells are enriched in the peritoneal cavity and are responsible for the production of most of the circulating IgM in normal mice (13). The physiological functions of these cells are still unknown, but several studies suggest that they are a first line of defense against infection (14, 15, 16, 17, 18). How autoreactive B cells like those that bind DNA fit into this picture is not known. B-1 cells may also contribute to autoantibody production in disease (13, 19, 20, 21, 22). For example, B-1 cells are responsible for autoantibody secretion causing hemolytic anemia in anti-RBC Tg mice (23), and autoimmune NZB and motheaten mice have expanded B-1 cell populations (19, 20) that produce autoantibodies. Thus, autoreactive B-1 cells can contribute to autoimmune disease.

The regulation of autoreactive B cells, including differentiation to B-1, is controlled by many factors. Ag concentration, the nature of the Ag, the location of the Ag, and the affinity of the B cell receptor (BCR) for Ag can all affect B cell signaling and hence B cell regulation (24, 25, 26, 27, 28, 29, 30). B cell coreceptors modulate the strength of the signal through the BCR and can also affect regulation. Of particular importance are CD19 and CD22. CD19 amplifies BCR signaling by increasing the protein tyrosine kinase activity of Src family protein tyrosine kinases (31). CD22 is able to associate with a tyrosine-specific phosphatase, SHP-1, to negatively regulate BCR signaling (32). Coligation of CD19 and BCR decreases the threshold for BCR-dependent stimulation (33). Conversely, ligation of CD22 raises the threshold for which BCR signaling activates a B cell (32). Thus, these coreceptors serve to raise and lower the Ag concentration required for B cell triggering. They also have a role in regulating the size of the B-1 cell subset. B-1 cell numbers are increased in mice that overexpress CD19 (34) and in CD22-deficient mice (35, 36). Conversely, their numbers are significantly decreased in CD19-deficient mice (34, 37). The fate of B cells destined for differentiation to B-1 in CD19-deficient mice is not known. Do they undergo cell death or do they follow a different differentiative pathway?

In this report, we examine the regulation of B cells specific for the RNP Sm, a target of the immune system in human and mouse lupus. We demonstrate that anti-Sm B cells are regulated in nonautoimmune mice by differentiation to B-1. Our studies of the regulation of anti-Sm B cells are facilitated by µ-chain Tg mice using an unmutated, rearranged VHJ558 gene from the MRL-Mp/lpr/lpr anti-Sm hybridoma 2-12 (38). 2-12H Tg mice generate substantial numbers of B cells specific for Sm and ssDNA (39). Most of the autoreactive B cells in 2-12H Tg spleens are transitional. The remainder are mature B-2 cells. This dominance of transitional anti-Sm B cells suggests an inability of anti-Sm B cells to become mature B-2 cells or to persist as B-2 cells. Despite the large number of anti-Sm B cells in these mice, they have serum anti-Sm levels that are equal to those of non-Tg littermate mice. However, immunization with mouse small nuclear RNPs (snRNPs) induces an anti-Sm response, indicating that anti-Sm B cells are functional and ignorant of endogenous levels of Sm (39). Here, we report that 2-12H Tg mice have a high frequency of peritoneal anti-Sm B-1 cells. The transfer of splenic B cells from 2-12H Tg mice to irradiated non-Tg littermates indicates that splenic anti-Sm B cells can differentiate to B-1. The differentiation of anti-Sm B cells to B-1 is sensitive to signal strength, as decreasing signal strength through the elimination of CD19 expression directs differentiation to B-2 and inhibits differentiation to B-1. Serum anti-Sm levels are also affected by changes in CD19 and CD22 expression; increasing the level of CD19 or eliminating CD22 increases serum anti-Sm levels. We suggest that differentiation to B-1 helps maintain ignorance to Sm by raising their activation threshold.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Mice

2-12H Tg mice have been described previously (39) and are maintained in our colony at the University of North Carolina by backcrossing to C.B-17 mice. Offspring are identified by PCR analysis of tail genomic DNA as previously described (39). CD19-/-, and CD22-/- mice, and hCD19 Tg mice were described previously (34, 37) and bred with 2-12H Tg mice.

CD19-/- and CD22-/- mice were identified by PCR analysis of tail genomic DNA. The primer pairs for the PCR were designed to flank the portion of the CD19 and CD22 genes that contained the neo insertion (34, 37). The PCR products from wild-type mice result in a 758-bp product for CD19 and 444 bp for CD22, whereas knockout mice result in no product. Forward primer GGT GGA TGG ATA GTC CCA GTG and reverse primer CGA CTT GAA AGC CTT TCA AGG C were used for identification of CD19-/- mice. Forward primer GTC CCA CCC AGA CGA GAC ACC and reverse primer CCG AGA CAT TGA GGT GAA TGG G were used for identification of CD22-/- mice.

hCD19 Tg mice were identified by analysis of PBLs. After lysis of RBC, the cells were incubated with anti-human CD19 PE-conjugated Ab for 30 min on ice and washed. The stained cells were analyzed by flow cytometry. hCD19 Tg mice were determined by positive staining with anti-human CD19 Ab using non-hCD19 Tg mice as control for background staining. Mean fluorescence intensity of hCD19+/+ mice was twice as much as that of hCD19+/- mice.

Flow cytometry

The Abs used specific for IgMa (DS-1), IgMb (AF6-78), B220 (RA3-6B2), HAS (30-F1), CD23 (B3B4), CD43 (S7), and CD5 (53-7.3) were obtained from PharMingen (San Diego, CA) and were fluoresceinated, biotinylated, or conjugated to PE. In three-color experiments, directly fluoresceinated and PE-conjugated Abs were combined with a biotinylated Sm, which was revealed with streptavidin-PerCP. In four-color experiments, biotinylated ssDNA (Life Technologies, Grand Island, NY) was revealed with streptavidin-PerCP, and Sm was directly Cy5 (Molecular Probes, Eugene, OR) labeled and combined with directly fluoresceinated and PE-conjugated Abs. To detect membrane expression of various molecules, single-cell suspensions were prepared in RPMI 1640 medium (HyClone, Logan, UT) containing 0.1% sodium azide and 3.0% bovine calf serum (HyClone). Cells were incubated with previously determined optimal amounts of Ab in 50 µl of buffer for 20 min, after which they were washed three times with buffer and incubated with second-step reagents. After washing as before, the cells were analyzed using a FACScan and FACSCalibur (Becton Dickinson, Mountain View, CA). Data were analyzed using WinMDI (The Scripps Institute, La Jolla, CA). All data represent cells that fall within the lymphocyte gate determined by forward and 90° light scatter. One to 5 x 105 cells per sample were analyzed. All contour plots are 5% probability.

Adoptive transfer

Splenic B cells from 2-12 mice were enriched using a mouse B cell recovery column kit (Cedarlane Laboratories, Hornby, Ontario, Canada) according to the manufacturer’s instructions. Approximately 2 x 107 cells were transferred i.v. into sublethally (500 rad) irradiated non-Tg littermates. Spleen and peritoneal cells were taken after 5 days for flow cytometry analysis. For cell division analysis, spleen cells were labeled with CFSE (Molecular Probes) as described by Lyons and Parish (40) before adoptive transfer. Briefly, the CFSE stock solution was prepared at 5 mM in DMSO. Spleen cells were harvested and washed with PBS three times and resuspended at 2x 107 cells/ml in PBS. Immediately before labeling, the CFSE was thawed and diluted to 10 µM in a volume of PBS equal to that in which the cells were suspended. The two volumes were mixed together and incubated at room temperature for 10 min. An equal volume of calf serum was added to quench the labeling. The labeled cells were then washed three times with PBS and transferred i.v.

Serum ELISA

Quantitation of anti-Sm Abs and total IgM in mouse serum was done by ELISA as previously described (39). Briefly, 96-well PVC plates were coated with either Sm or goat anti-mouse IgM (Southern Biotechnology Associates, Birmingham, AL) in borate-buffered saline, washed, and blocked with borate-buffered saline/BSA/Tween 20. Mouse sera were diluted serially in borate-buffered saline/BSA/Tween 20 and added to Ag-coated plates in duplicate and then incubated overnight. After washing, goat anti-mouse IgM alkaline phosphatase (Southern Biotechnology Associates) was added and the anti-mouse IgM was revealed by the addition of 1 mg/ml p-nitrophenyl phosphate (Sigma, St. Louis, MO) in 0.01 M diethanolamine buffer. OD405 was determined after 90–120 min of incubation. Serum titers of anti-Sm were determined by generation of a standard curve for each assay using serial dilutions of mouse IgM of a known concentration.

LPS stimulation

Splenic and peritoneal exudate cells were harvested, washed, and resuspended at 1x 106 cells/ml in complete RPMI 1640 and incubated for 72 h in 5% CO2 in the presence or absence of 50 µg/ml LPS. Supernatants from cultures were tested by ELISA for anti-Sm and total IgM production as described above.

Statistical analysis

Statistical analysis was performed using Student’s t test. A value of p < 0.05 was considered to be significant.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Anti-Sm B-1 cells are present in peritoneums of 2-12H Tg mice

We previously demonstrated that 15–35% of splenic B cells in nonautoimmune 2-12H Tg mice are anti-Sm (Table IGo and Ref. 39). Immunofluorescence studies indicate that most of these B cells are transitional, as they are IgMhigh, HSAhigh, CD23-, CD43-, and CD5- (Fig. 1GoA and Ref. 39). They also express intermediate levels of CD21 consistent with transitional B cells, indicating that they are not marginal zone B cells. However, some appear to be mature B cells, since an IgMlow, HSAlow, CD23+, CD43-, and CD5- populations can be detected. We have not detected anti-Sm B cells in the spleen that have a B-1 phenotype. However, Fig. 1Go shows that there is a large population of anti-Sm B-1 cells in the peritoneum. These cells were missed in the previous analysis (39) because they were inadvertently gated out. They are IgMhigh, CD23-, CD43+, and CD5+ (Fig. 1GoA), and they are larger and more granular than the CD23+ B cells of the peritoneum (Fig. 1GoB). They constitute ~30% of the B-1 subset (Table IGo). Nearly all of the peritoneal anti-Sm B cells express CD5, indicating that they are predominately B-1a. Interestingly, ~6% of the B-1 repertoire of non-Tg mice are anti-Sm (Table IGo and Fig. 1GoA), indicating that they are a significant component of the normal B-1 repertoire in mice.


View this table:
[in this window]
[in a new window]
 
Table I. Lymphocyte populations

 


View larger version (46K):
[in this window]
[in a new window]
 
FIGURE 1. Flow cytometry analysis of spleen and peritoneal B cells from 2-12H Tg and non-Tg littermates. A, Spleen and peritoneal cells were stained with B220-PE, Sm-biotin, and FITC-labeled IgM (IgMb for non-Tg and IgMa for 2-12H Tg mice), CD23, CD43, or CD5. All histograms are gated on B220+ cells. B, The size (forward light scatter (FSC)) and granularity (side light scatter (SSC)) of peritoneal anti-Sm B-1 cells (bold line) and CD23+ B-2 cells (thin line) from 2-12H Tg mice.

 
B cell nonresponsiveness to LPS accompanies anergy (41, 42, 43). LPS stimulation of splenic B cells from 2-12H Tg mice induces secretion of anti-Sm Abs, suggesting that they are functional (39). Indeed, immunization with snRNPs induces an anti-Sm response. To determine whether peritoneal anti-Sm B-1 cells are also responsive to LPS, peritoneal B cells were cultured with LPS at 50 µg/ml. Fig. 2Go shows that peritoneal anti-Sm B cells of 2-12H Tg mice are responsive to LPS. IgM levels are similar to those of non-Tg littermates and the level of anti-Sm is 5-fold higher in 2-12H Tg cultures than in non-Tg cultures. In contrast, LPS stimulation of non-Tg mouse peritoneal B cells induces IgM Ab secretion, but little anti-Sm autoantibody secretion. Thus, by this criterion peritoneal anti-Sm B-1 cells are functional.



View larger version (15K):
[in this window]
[in a new window]
 
FIGURE 2. Ab secretion by LPS-stimulated peritoneal B cells of 2-12H Tg and non-Tg littermate mice. Both total IgM ({blacksquare}) and anti-Sm ({square}) concentrations (in µg/ml) were measured. A total of eight 2-12H Tg and eight non-Tg littermates were analyzed in two experiments. All LPS-stimulated cultures were significantly different from their unstimulated counterparts. *, significant difference (p < 0.001) between LPS-stimulated 2-12H Tg and non-Tg peritoneal B cells.

 
Splenic anti-Sm B cells have the potential to differentiate to B-1

To investigate the relationship between the predominantly transitional splenic anti-Sm B cells and the mature peritoneal anti-Sm B-1 cells, we transferred splenic B cells from 2-12H Tg mice to sublethally irradiated littermate mice. Both spleen and peritoneal B cells were examined 5 days later. Donor B cells were identified by IgMa staining, as endogenous B cells are IgMb. In the spleen, donor anti-Sm B cells are CD23-, CD43-, and CD5- and thus appear to be transitional (Fig. 3GoA). Donor B cells are also found in the peritoneum, including many that bind Sm. Interestingly, here the majority of anti-Sm B cells are B-1 (i.e., IgMhigh, CD23-, CD43+, and CD5+) (Fig. 3GoA).



View larger version (37K):
[in this window]
[in a new window]
 
FIGURE 3. A, Adoptively transferred splenic B cells from 2-12H Tg mice give rise to peritoneal anti-Sm B-1 cells of recipient mice. IgMa staining identifies B cells of donor origin, and both the spleen and peritoneum of recipient mice 5 days after transfer are shown. The phenotype of peritoneal B cells of unmanipulated 2-12H Tg mice is shown for comparison (right column). All dot plots are gated on IgMa-positive cells. B, Transferred 2-12H Tg splenic B cells undergo few divisions after transfer. Shown are the divisions for total B cells (thin line) and anti-Sm B cells (bold line) in recipient spleen and peritoneum. Most transferred cells undergo between zero and two divisions as indicated.

 
To rule out that the appearance of peritoneal B-1 cells in recipient mice is due to the proliferation of an undetected population of splenic B-1 cells, we used an intracellular fluorescent labeling method to monitor in vivo cell division of the adoptively transferred splenic B cells. Spleen cells were transferred as described above after CFSE labeling. Fig. 3GoB shows that 5 days after transfer, nearly all of the donor peritoneal anti-Sm B cells, identified by their CFSE staining, have undergone only one or two divisions. These findings indicate that expansion of an undetected population of contaminating B-1 cells of donor origin cannot be responsible for the peritoneal anti-Sm B-1 cell population in recipient mice. Thus, splenic anti-Sm B cells have differentiated to B-1 in recipient mice. We also note that there is a large population of B-1 cells of donor origin that do not bind Sm, indicating that B cells of other specificities in 2-12H Tg spleens are selected into the B-1 subset.

Altered B cell coreceptor expression affects anti-Sm B cell differentiation

To investigate the effect of signal strength on anti-Sm B cell differentiation, we varied the levels of two B cell coreceptors, CD19 and CD22. 2-12H Tg/CD19-/- mice have 40% fewer B cells in the spleen than 2-12H Tg mice (p < 0.05, Table IGo), consistent with previous findings (37). The absence of CD19 has a similar effect on non-Tg mice. However, the frequency of anti-Sm B cells increases from 30% in 2-12H Tg mice to 47% in 2-12H Tg/CD19-/- mice (p < 0.05), a 57% increase, indicating that anti-Sm B cell development is favored in the absence of CD19. In contrast to 2-12H Tg mice in which splenic anti-Sm B cells are mostly CD23- transitional B cells, splenic anti-Sm B cells of 2-12H Tg/CD19-/- mice have a mature B-2 cell phenotype (i.e., CD23+, CD43-, CD5-, and HSAlow) (Fig. 4Go).



View larger version (55K):
[in this window]
[in a new window]
 
FIGURE 4. Flow cytometry analysis of spleen and peritoneal B cells from 2-12H Tg/CD19-/-, 2-12H Tg/hCD19+/+, and 2-12H Tg/CD22-/- mice. Spleen and peritoneal cells were stained with B220-PE, Sm-biotin, and FITC-labeled IgM (IgMb for non-Tg/CD19-/- and IgMa for 2-12H Tg/CD19-/- mice), CD23, CD43, and CD5. All histograms and dot plots are gated on B220+ cells.

 
The absence of CD19 also has dramatic effects on peritoneal anti-Sm B cells. The percentage of peritoneal B cells decreases 10-fold (70–7%) in 2-12H Tg with the elimination of CD19 (Table IGo and Fig. 4Go), consistent with the finding that CD19-/- mice are deficient in B-1 cell differentiation (37, 44). Moreover, the proportion of anti-Sm B cells decreases from 32.5% to 5% (Table IGo), and thus the total number of peritoneal anti-Sm B cells decreases dramatically (Table IGo). Like splenic anti-Sm B cells, peritoneal anti-Sm B cells of 2-12H Tg/CD19-/- mice are B-2 (i.e., IgMhigh, CD23+, CD43-, and CD5-) (Fig. 4Go). Thus, in the absence of CD19 anti-Sm B cells differentiate to B-2 rather than to B-1.

Overexpression of CD19 increases the number of B-1 cells. The level of CD19 can be varied using mice hemizygous for the human CD19 transgene (hCD19+/-) and mice that are homozygous for the hCD19 transgene (hCD19+/+) (34). We have examined anti-Sm B cells in 2-12H Tg mice that are either hCD19+/- or hCD19+/+. The total number of splenic lymphocytes is reduced in 2-12H Tg/hCD19+/+ mice and to a lesser degree in 2-12H Tg/hCD19+/- mice. This is consistent with previous reports of overexpression of CD19 (37). 2-12H Tg/hCD19+/- and 2-12H Tg/hCD19+/+ mice have 38 and 58% fewer B cells than 2-12H Tg mice, respectively (Table IGo). Oddly, the frequency of anti-Sm B cells is lower in 2-12H Tg/hCD19+/- mice (18.1%) than in 2-12H Tg/hCD19+/+ mice (25.8%) (Table IGo). The latter frequency is not different from that in 2-12H Tg mice. As in 2-12H Tg mice, the anti-Sm B cells in hCD19 Tg mice are mostly transitional (i.e., IgMhigh, CD23-, CD43-, and CD5-) (Fig. 4Go).

The number and frequency of the peritoneal B cells of 2-12H Tg/hCD19 Tg mice is similar to that of 2-12H Tg mice (Table IGo). However, the number of peritoneal B-1 cells increases as the dose of hCD19 increases. Thus, 90% of 2-12H Tg/hCD19+/- and 96% of 2-12H Tg/hCD19+/+ peritoneal B cells exhibit a B-1 phenotype (Fig. 4Go), compared with 72% in 2-12H Tg mice. This is consistent with the finding of Sato et al. (34) that increased CD19 expression results in an increased frequency of B-1 cells in the peritoneum. In addition, the frequency of anti-Sm B cells increases by 2-fold in hCD19+/+ mice relative to 2-12H Tg mice (Table IGo). Phenotypic analysis indicates that all of the anti-Sm B cells are B-1, as they are IgMhigh, CD23-, CD43+, and CD5+ (Fig. 4Go). As in 2-12H Tg mice, all anti-Sm B-1 cells in hCD19 Tg mice carrying the 2-12H transgene are CD5+ and therefore B-1a.

CD22 is a negative regulator of B cell signaling through its association with SHP-1 (32). To determine how CD22 influences differentiation of anti-Sm B-1 and transitional B cells, we bred 2-12H Tg/CD22-/- mice. Although the frequency of splenic B cells in both 2-12H Tg and 2-12H Tg/CD22-/- mice is the same, the absence of CD22 decreases by 48% the number of splenic lymphocytes. A lack of CD22 also results in a decrease in the total number and frequency of anti-Sm B cells in 2-12H Tg mice (Table IGo). However, the anti-Sm B cells remain transitional (i.e., IgMhigh, CD23-, CD43-, and CD5-) (Fig. 4Go).

In the peritoneum the number of lymphocytes increases 4-fold over CD22 intact mice, and the frequency of the B-1 cells increases from 78 to 98% in 2-12H Tg mice (Table IGo). Although the frequency of anti-Sm B cells decreases in 2-12H Tg as a result of the absence of CD22, the total number of anti-Sm B cells increases as a result of the increase in the total number of peritoneal B cells in CD22-/- mice (Table IGo). However, in CD22-/- mice they are B-1 (i.e., IgMhigh, CD23-, and CD43+, and CD5+) (Fig. 4Go).

Serum anti-Sm levels in 2-12H Tg mice are affected by changes in coreceptor expression

Serum anti-Sm levels in 2-12H Tg mice were evaluated by ELISA. As we showed previously (39), serum anti-Sm levels in 2-12H Tg mice are not significantly different from those of non-Tg littermate mice, despite the substantially higher number of anti-Sm B cells in the spleens and peritoneums of 2-12H Tg mice (Fig. 5Go). However, 2-12H/CD22-/-, 2-12H/hCD19+/+, and 2-12H Tg/hCD19+/- mice have levels of anti-Sm that are significantly higher than those of 2-12H Tg mice (p < 0.05) and their non-Tg counterparts (p < 0.05) (Fig. 5Go). These levels are comparable to those of 2-12H Tg MRL-Mp/lpr/lpr mice (Fig. 5Go). Conversely, 2-12H Tg/CD19-/- mice, which have no anti-Sm B-1 cells, have significantly decreased serum anti-Sm levels (p < 0.05) compared with 2-12H Tg mice. This suggests that changes in B-1 cell sensitivity to signaling affects serum anti-Sm levels.



View larger version (23K):
[in this window]
[in a new window]
 
FIGURE 5. Serum IgM Ab levels are affected by changes in CD19 and CD22 expression. Both serum IgM anti-Sm levels (A) and total serum IgM levels (B) were measured by ELISA.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We have demonstrated the existence of anti-Sm B-1 cells in the peritoneum of nonautoimmune 2-12H Tg mice where they account for ~30% of the B-1 repertoire. This is in addition to the anti-Sm B cells in the spleens of these mice, the majority of which are transitional. We also show a direct relationship between the splenic and peritoneal anti-Sm B cells; adoptive transfer of splenic anti-Sm B cells results in their differentiation to B-1 and movement to the peritoneum. Thus, splenic anti-Sm B cells are capable of differentiation to B-1.

A B-2 to B-1 differentiative pathway was originally proposed by Wortis and colleagues (45), and we have demonstrated that B cells specific for phosphatidyl choline (PtC), which are exclusively B-1 in normal mice, follow this pathway of differentiation in vivo (46, 47). It remains to be determined whether differentiation to B-1 occurs throughout adult life. The peritoneal B-1 cell population develops early in life and maintenance of the B-1 population occurs by the self-renewal capacity of these cells (48, 49). It does not require continuous infusion of new B cells, as is required for the B-2 population (48, 49). However, this does not preclude that some cells enter the B-1 subset in adult life since not all B-1 cells may have the same half-life. Because anti-Sm transitional B cells are continuously generated by the adult bone marrow, there may be a constant flow of anti-Sm B cells to the B-1 subset throughout life. Alternatively, their differentiation may be blocked and they may instead undergo apoptosis, despite their capacity to differentiate to B-1. Such a block might be due to a negative feedback from already differentiated B-1 cells. In this regard, we note that there are 30 times as many anti-Sm transitional B cells as anti-Sm B-1 cells in 2-12H Tg mice (Table IGo). If the anti-Sm transitional B cells all differentiate to B-1, then by necessity the anti-Sm B-1 cells must be short-lived. Preliminary experiments suggest that the half-life of anti-Sm B-1 cells is not short and is equal to that of non-Tg B-1 cells. Thus, many transitional anti-Sm B cells probably undergo apoptosis in the spleen as previously suggested (39). Experiments are currently underway to resolve this issue.

Differentiation of anti-Sm B cells to B-1 appears to be governed by the strength of the signal delivered by Ag. Decreasing the strength of Ag receptor signaling by CD19 elimination resulted in B cell differentiation into B-2 cells rather than into B-1 cells. Thus, weak signals generated through the Ag receptor may result in transitional B cell differentiation into B-2 cells rather than undergoing apoptosis or differentiation to B-1. Since B-1 cell numbers are greatly reduced in CD19-deficient mice, the assumption was that signal strength was insufficient to support the long-term survival of B-1 cells (34). However, the current study suggests that appropriate signals generated through the Ag receptor are required for B cell development into B-1 cells. In support of this, overexpression of CD19 or elimination of CD22 significantly increased the number of 2-12H B-1 B cells, while the numbers of 2-12H B-2 cells in these mice were decreased (Table IGo and Fig. 4Go). Furthermore, consistent with B-1 as the origin of circulating IgM, serum anti-Sm autoantibody levels in 2-12H Tg/hCD19+/+ or +/- and 2-12H Tg/CD22-/- mice were 4- to 5-fold higher than the levels in 2-12H Tg mice and non-Tg mice (Fig. 5Go). This is comparable to the levels in 2-12H Tg MRL-Mp/lpr/lpr mice (Fig. 5Go). Thus, activation thresholds regulate B-1 cell differentiation in addition to regulating tolerance and the levels of serum anti-Sm.

The differentiation of anti-Sm B cells to B-1 and the absence of higher serum anti-Sm in 2-12H Tg mice relative to non-Tg mice is paradoxical (Fig. 5Go). B cells are selected by Ag for recruitment into the B-1 cell subset, and B-1 cells are responsible for most of the circulating IgM in unmanipulated mice (13, 50). Indeed, anti-PtC Tg mice have ~100-fold more serum anti-PtC than non-Tg littermates due to the increase in anti-PtC B-1 cell numbers (51). Why then do 2-12H Tg mice not have higher serum anti-Sm levels than non-Tg littermates, given the higher number of anti-Sm B-1 cells? One possibility is that migration to the peritoneum removes these cells from contact with other cells or molecules required for activation and differentiation to Ab-secreting cells. For example, exposure to the activating Ag in the peritoneum may not be sufficient to drive differentiation of anti-Sm B-1 cells to Ab-secreting cells. Another possibility is that differentiation to B-1 is accompanied by changes in the B cell itself that decrease its sensitivity to Ag. One change induced by differentiation to B-1 relevant to this is the expression of CD5, a negative regulator of BCR signaling through its association with the phosphatase SHP-1 (52, 53). This association would increase the amount of Ag required for activation. Hippen et al. (54) have recently demonstrated that CD5 is expressed by anergic anti-hen egg lysozyme (HEL) B cells and that it is responsible for the very low levels of circulating anti-HEL. In the absence of CD5, anergic anti-HEL B cells produce high levels of circulating anti-HEL similar to those found in mice with functional anti-HEL B cells. Thus, CD5 is instrumental in blocking activation of anergic B cells in this model. In an analogous way, CD5 expression could inhibit activation of anti-Sm B cells and account for the low levels of anti-Sm in unimmunized 2-12H Tg mice (Fig. 5Go and Ref. 39). Thus, differentiation to B-1 may be an essential component in maintaining ignorance to Sm. Increasing the level of Sm Ag could overcome the negative effects of CD5 on BCR signaling and account for the ability to activate these cells upon immunization with snRNPs (39). This may relate to the finding that all anti-Sm B-1 cells of 2-12H Tg mice express CD5, as do the peritoneal anti-Sm B-1 cells of non-Tg littermates. Thus, regulation of CD5 expression may control the ability of B-1 cells to be activated and hence the autoantibodies secreted by B-1 cells.

In summary, we have demonstrated that anti-Sm B cells differentiate to B-1 and that the strength of the signal provided by Ag determines whether an anti-Sm B cell differentiates to B-2 or to B-1. In addition, alteration of the activation threshold increases or decreases the level of serum anti-Sm, indicating that the activation threshold setting determines the level of circulating Ab. We suggest that differentiation to B-1 helps maintain ignorance to Sm in nonautoimmune mice through the expression of negative regulators of BCR signaling such as CD5. Alterations in the threshold setting or ability of B cells to differentiate to B-1 could be a predisposing factor in production of autoantibodies in disease. Thus, anti-Sm B cells provide a new perspective on maintaining tolerance to self-Ags targeted in lupus.


    Acknowledgments
 
We dedicate this manuscript to the memory of Geoffrey Haughton. We thank Dr. Larry Arnold and the University of North Carolina, Chapel Hill Flow Cytometry Facility for their excellent technical assistance and advice with the flow cytometry. We are also grateful to Ann Wolthusen for her work with the mouse breeding and typing and to all members of the laboratory for their many helpful discussions.


    Footnotes
 
1 This work was supported by National Institutes of Health Grants AI29576 and AI43587 and by a grant from the Arthritis Foundation. Back

2 Address correspondence and reprint requests to Dr. Stephen H. Clarke, Department of Microbiology and Immunology, CB 7290, 804 MEJB, University of North Carolina, Chapel Hill, NC 27599. Back

3 Abbreviations used in the paper: RNP, ribonucleoprotein; Tg, transgenic; BCR, B cell receptor; PtC, phosphatidyl choline; HEL, hen egg lysozyme. Back

Received for publication October 5, 2000. Accepted for publication December 4, 2000.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Tan, E. M.. 1989. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv. Immunol. 44:93.[Medline]
  2. Chan, O. T., L. G. Hannum, A. M. Haberman, M. P. Madaio, M. J. Shlomchik. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189:1639.[Abstract/Free Full Text]
  3. Chen, C., Z. Nagy, M. Z. Radic, R. R. Hardy, D. Huszar, S. A. Camper, M. Weigert. 1995. The site and stage of anti-DNA B-cell deletion. Nature 373:252.[Medline]
  4. Erikson, J., M. Z. Radic, S. A. Camper, R. R. Hardy, C. Carmack, M. Weigert. 1991. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature 349:331.[Medline]
  5. Wang, H., M. J. Shlomchik. 1999. Autoantigen-specific B cell activation in Fas-deficient rheumatoid factor immunoglobulin transgenic mice. J. Exp. Med. 190:639.[Abstract/Free Full Text]
  6. Offen, D., L. Spatz, H. Escowitz, S. Factor, B. Diamond. 1992. Induction of tolerance to an IgG autoantibody. Proc. Natl. Acad. Sci. USA 89:8332.[Abstract/Free Full Text]
  7. Tsao, B. P., A. Chow, H. Cheroutre, Y. W. Song, M. E. McGrath, M. Kronenberg. 1993. B cells are anergic in transgenic mice that express IgM anti-DNA antibodies. Eur. J. Immunol. 23:2332.[Medline]
  8. Gay, D., T. Saunders, S. Camper, M. Weigert. 1993. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med. 177:999.[Abstract/Free Full Text]
  9. Xu, H., H. Li, E. Suri-Payer, R. R. Hardy, M. Weigert. 1998. Regulation of anti-DNA B cells in recombination-activating gene- deficient mice. J. Exp. Med. 188:1247.[Abstract/Free Full Text]
  10. Mandik-Nayak, L., S. J. Seo, C. Sokol, K. M. Potts, A. Bui, J. Erikson. 1999. MRL-lpr/lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti-double-stranded DNA B cells. J. Exp. Med. 189:1799.[Abstract/Free Full Text]
  11. Casali, P., S. E. Burastero, M. Nakamura, G. Inghirami, A. L. Notkins. 1987. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 236:77.[Abstract/Free Full Text]
  12. Hardy, R. R., K. Hayakawa, M. Shimizu, K. Yamasaki, T. Kishimoto. 1987. Rheumatoid factor secretion from human Leu-1+ B cells. Science 236:81.[Abstract/Free Full Text]
  13. Hayakawa, K., R. R. Hardy, M. Honda, L. A. Herzenberg, A. D. Steinberg. 1984. Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc. Natl. Acad. Sci. USA 81:2494.[Abstract/Free Full Text]
  14. Herzenberg, L. A.. 1989. Toward a layered immune system. Cell 59:953.[Medline]
  15. Casali, P., E. W. Schettino. 1996. Structure and function of natural antibodies. Curr. Top. Microbiol. Immunol. 210:167.[Medline]
  16. Boes, M., A. P. Prodeus, T. Schmidt, M. C. Carroll, J. Chen. 1998. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J. Exp. Med. 188:2381.[Abstract/Free Full Text]
  17. Paciorkowski, N., P. Porte, L. D. Shultz, T. V. Rajan. 2000. B1 B lymphocytes play a critical role in host protection against lymphatic filarial parasites. J. Exp. Med. 191:731.[Abstract/Free Full Text]
  18. Baumgarth, N., O. C. Herman, G. C. Jager, L. E. Brown, L. A. Herzenberg, J. Chen. 2000. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J. Exp. Med. 192:271.[Abstract/Free Full Text]
  19. Hayakawa, K., R. R. Hardy, D. R. Parks, L. A. Herzenberg. 1983. The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice. J. Exp. Med. 157:202.[Abstract/Free Full Text]
  20. Sidman, C. L., L. D. Shultz, R. R. Hardy, K. Hayakawa, L. A. Herzenberg. 1986. Production of immunoglobulin isotypes by Ly-1+ B cells in viable motheaten and normal mice. Science 232:1423.[Abstract/Free Full Text]
  21. Sherr, D. H., M. E. Dorf, M. Gibson, C. L. Sidman. 1987. Ly-1 B helper cells in autoimmune "viable motheaten" mice. J. Immunol. 139:1811.[Abstract]
  22. Hayakawa, K., R. R. Hardy. 1988. Normal, autoimmune, and malignant CD5+ B cells: the Ly-1 B lineage?. Annu. Rev. Immunol. 6:197.[Medline]
  23. Murakami, M., T. Tsubata, M. Okamoto, A. Shimizu, S. Kumagai, H. Imura, T. Honjo. 1992. Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice. Nature 357:77.[Medline]
  24. Fulcher, D. A., A. B. Lyons, S. L. Korn, M. C. Cook, C. Koleda, C. Parish, B. Fazekas de St. Groth, A. Basten. 1996. The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J. Exp. Med. 183:2313.[Abstract/Free Full Text]
  25. Nemazee, D. A., K. Burki. 1989. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 337:562.[Medline]
  26. Goodnow, C. C., J. Crosbie, S. Adelstein, T. B. Lavoie, S. J. Smith-Gill, R. A. Brink, H. Pritchard-Briscoe, J. S. Wotherspoon, R. H. Loblay, K. Raphael, et al 1988. Altered immunoglobulin expression and functional silencing of self- reactive B lymphocytes in transgenic mice. Nature 334:676.[Medline]
  27. Hartley, S. B., J. Crosbie, R. Brink, A. B. Kantor, A. Basten, C. C. Goodnow. 1991. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 353:765.[Medline]
  28. Russell, D. M., Z. Dembic, G. Morahan, J. F. Miller, K. Burki, D. Nemazee. 1991. Peripheral deletion of self-reactive B cells. Nature 354:308.[Medline]
  29. Sandel, P. C., J. G. Monroe. 1999. Negative selection of immature B cells by receptor editing or deletion is determined by site of antigen encounter. Immunity 10:289.[Medline]
  30. Kouskoff, V., S. Famiglietti, G. Lacaud, P. Lang, J. E. Rider, B. K. Kay, J. C. Cambier, D. Nemazee. 1998. Antigens varying in affinity for the B cell receptor induce differential B lymphocyte responses. J. Exp. Med. 188:1453.[Abstract/Free Full Text]
  31. Fujimoto, M., J. C. Poe, P. J. Jansen, S. Sato, T. F. Tedder. 1999. CD19 amplifies B lymphocyte signal transduction by regulating Src- family protein tyrosine kinase activation. J. Immunol. 162:7088.[Abstract/Free Full Text]
  32. Doody, G. M., L. B. Justement, C. C. Delibrias, R. J. Matthews, J. Lin, M. L. Thomas, D. T. Fearon. 1995. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 269:242.[Abstract/Free Full Text]
  33. Carter, R. H., D. T. Fearon. 1992. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256:105.[Abstract/Free Full Text]
  34. Sato, S., N. Ono, D. A. Steeber, D. S. Pisetsky, T. F. Tedder. 1996. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157:4371.[Abstract]
  35. Sato, S., A. S. Miller, M. Inaoki, C. B. Bock, P. J. Jansen, M. L. Tang, T. F. Tedder. 1996. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 5:551.[Medline]
  36. O’Keefe, T. L., G. T. Williams, S. L. Davies, M. S. Neuberger. 1996. Hyperresponsive B cells in CD22-deficient mice. Science 274:798.[Abstract/Free Full Text]
  37. Engel, P., L. J. Zhou, D. C. Ord, S. Sato, B. Koller, T. F. Tedder. 1995. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3:39.[Medline]
  38. Bloom, D. D., J. L. Davignon, M. W. Retter, M. J. Shlomchik, D. S. Pisetsky, P. L. Cohen, R. A. Eisenberg, S. H. Clarke. 1993. V region gene analysis of anti-Sm hybridomas from MRL/Mp-lpr/lpr mice. J. Immunol. 150:1591.[Abstract]
  39. Santulli-Marotto, S., M. W. Retter, R. Gee, M. J. Mamula, S. H. Clarke. 1998. Autoreactive B cell regulation: peripheral induction of developmental arrest by lupus-associated autoantigens. Immunity 8:209.[Medline]
  40. Lyons, A. B., C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171:131.[Medline]
  41. Pike, B. L., A. W. Boyd, G. J. Nossal. 1982. Clonal anergy: the universally anergic B lymphocyte. Proc. Natl. Acad. Sci. USA 79:2013.[Abstract/Free Full Text]
  42. Adams, E., A. Basten, C. C. Goodnow. 1990. Intrinsic B-cell hyporesponsiveness accounts for self-tolerance in lysozyme/anti-lysozyme double-transgenic mice. Proc. Natl. Acad. Sci. USA 87:5687.[Abstract/Free Full Text]
  43. Okamoto, M., M. Murakami, A. Shimizu, S. Ozaki, T. Tsubata, S. Kumagai, T. Honjo. 1992. A transgenic model of autoimmune hemolytic anemia. J. Exp. Med. 175:71.[Abstract/Free Full Text]
  44. Rickert, R. C., K. Rajewsky, J. Roes. 1995. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376:352.[Medline]
  45. Cong, Y. Z., E. Rabin, H. H. Wortis. 1991. Treatment of murine CD5- B cells with anti-Ig, but not LPS, induces surface CD5: two B-cell activation pathways. Int. Immunol. 3:467.[Abstract/Free Full Text]
  46. Clarke, S. H., L. W. Arnold. 1998. B-1 cell development: evidence for an uncommitted immunoglobulin (Ig)M+ B cell precursor in B-1 cell differentiation. J. Exp. Med. 187:1325.[Abstract/Free Full Text]
  47. Arnold, L. W., S. K. McCray, C. Tatu, S. H. Clarke. 2000. Identification of a precursor to phosphatidyl choline-specific B-1 cells suggesting that B-1 cells differentiate from splenic conventional B cells in vivo: cyclosporin A blocks differentiation to B-1. J. Immunol. 164:2924.[Abstract/Free Full Text]
  48. Hayakawa, K., R. R. Hardy, L. A. Herzenberg. 1985. Progenitors for Ly-1 B cells are distinct from progenitors for other B cells. J. Exp. Med. 161:1554.[Abstract/Free Full Text]
  49. Hayakawa, K., R. R. Hardy, A. M. Stall, L. A. Herzenberg. 1986. Immunoglobulin-bearing B cells reconstitute and maintain the murine Ly-1 B cell lineage. Eur. J. Immunol. 16:1313.[Medline]
  50. Forster, I., K. Rajewsky. 1987. Expansion and functional activity of Ly-1+ B cells upon transfer of peritoneal cells into allotype-congenic, newborn mice. Eur. J. Immunol. 17:521.[Medline]
  51. Arnold, L. W., C. A. Pennell, S. K. McCray, S. H. Clarke. 1994. Development of B-1 cells: segregation of phosphatidyl choline-specific B cells to the B-1 population occurs after immunoglobulin gene expression. J. Exp. Med. 179:1585.[Abstract/Free Full Text]
  52. Bikah, G., J. Carey, J. R. Ciallella, A. Tarakhovsky, S. Bondada. 1996. CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 274:1906.[Abstract/Free Full Text]
  53. Sen, G., G. Bikah, C. Venkataraman, S. Bondada. 1999. Negative regulation of antigen receptor-mediated signaling by constitutive association of CD5 with the SHP-1 protein tyrosine phosphatase in B-1 B cells. Eur. J. Immunol. 29:3319.[Medline]
  54. Hippen, K. L., L. E. Tze, T. W. Behrens. 2000. CD5 maintains tolerance in anergic B cells. J. Exp. Med. 191:883.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Immunol.Home page
R. Diz, S. K. McCray, and S. H. Clarke
B Cell Receptor Affinity and B Cell Subset Identity Integrate to Define the Effectiveness, Affinity Threshold, and Mechanism of Anergy
J. Immunol., September 15, 2008; 181(6): 3834 - 3840.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Wang, M. W. Nicholas, K. L. Conway, P. Sen, R. Diz, R. M. Tisch, and S. H. Clarke
EBV Latent Membrane Protein 2A Induces Autoreactive B Cell Activation and TLR Hypersensitivity.
J. Immunol., September 1, 2006; 177(5): 2793 - 2802.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
L. Mandik-Nayak, J. Racz, B. P. Sleckman, and P. M. Allen
Autoreactive marginal zone B cells are spontaneously activated but lymph node B cells require T cell help
J. Exp. Med., August 7, 2006; 203(8): 1985 - 1998.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Qian, K. L. Conway, X. Lu, H. M. Seitz, G. K. Matsushima, and S. H. Clarke
Autoreactive MZ and B-1 B-cell activation by Faslpr is coincident with an increased frequency of apoptotic lymphocytes and a defect in macrophage clearance
Blood, August 1, 2006; 108(3): 974 - 982.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. A. Culton, B. P. O'Conner, K. L. Conway, R. Diz, J. Rutan, B. J. Vilen, and S. H. Clarke
Early Preplasma Cells Define a Tolerance Checkpoint for Autoreactive B Cells
J. Immunol., January 15, 2006; 176(2): 790 - 802.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Ait-Azzouzene, L. Verkoczy, B. Duong, P. Skog, A. L. Gavin, and D. Nemazee
Split Tolerance in Peripheral B Cell Subsets in Mice Expressing a Low Level of Ig{kappa}-Reactive Ligand
J. Immunol., January 15, 2006; 176(2): 939 - 948.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. William, C. Euler, and M. J. Shlomchik
Short-Lived Plasmablasts Dominate the Early Spontaneous Rheumatoid Factor Response: Differentiation Pathways, Hypermutating Cell Types, and Affinity Maturation Outside the Germinal Center
J. Immunol., June 1, 2005; 174(11): 6879 - 6887.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. A. Steeves and T. N. Marion
Tolerance to DNA in (NZB x NZW)F1 Mice That Inherit an Anti-DNA VH as a Conventional {micro} H Chain Transgene but Not as a VH Knock-in Transgene
J. Immunol., June 1, 2004; 172(11): 6568 - 6577.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. F. Widhopf II, D. C. Brinson, T. J. Kipps, and H. Tighe
Transgenic Expression of a Human Polyreactive Ig Expressed in Chronic Lymphocytic Leukemia Generates Memory-Type B Cells That Respond to Nonspecific Immune Activation
J. Immunol., February 15, 2004; 172(4): 2092 - 2099.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. C. Poe, K. M. Haas, J. Uchida, Y. Lee, M. Fujimoto, and T. F. Tedder
Severely Impaired B Lymphocyte Proliferation, Survival, and Induction of the c-Myc:Cullin 1 Ubiquitin Ligase Pathway Resulting from CD22 Deficiency on the C57BL/6 Genetic Background
J. Immunol., February 15, 2004; 172(4): 2100 - 2110.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Qian, H. Wang, and S. H. Clarke
Impaired Clearance of Apoptotic Cells Induces the Activation of Autoreactive Anti-Sm Marginal Zone and B-1 B Cells
J. Immunol., January 1, 2004; 172(1): 625 - 635.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Wang and S. H. Clarke
Evidence for a Ligand-Mediated Positive Selection Signal in Differentiation to a Mature B Cell
J. Immunol., December 15, 2003; 171(12): 6381 - 6388.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. D. Aplin, C. L. Keech, A. L. de Kauwe, T. P. Gordon, D. Cavill, and J. McCluskey
Tolerance through Indifference: Autoreactive B Cells to the Nuclear Antigen La Show No Evidence of Tolerance in a Transgenic Model
J. Immunol., December 1, 2003; 171(11): 5890 - 5900.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Gary-Gouy, J. Harriague, G. Bismuth, C. Platzer, C. Schmitt, and A. H. Dalloul
Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production
Blood, December 15, 2002; 100(13): 4537 - 4543.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
P. L. Cohen
Autoimmunity and Lymphoproliferation: Two Genes are Worse than One
Mol. Interv., November 1, 2002; 2(7): 427 - 430.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
S.-C. Wong, W.-K. Chew, J. E.-L. Tan, A. J. Melendez, F. Francis, and K.-P. Lam
Peritoneal CD5+ B-1 Cells Have Signaling Properties Similar to Tolerant B Cells
J. Biol. Chem., August 16, 2002; 277(34): 30707 - 30715.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. J. Chumley, J. M. Dal Porto, and J. C. Cambier
The Unique Antigen Receptor Signaling Phenotype of B-1 Cells Is Influenced by Locale but Induced by Antigen
J. Immunol., August 15, 2002; 169(4): 1735 - 1743.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
C. H. Nielsen and R. G. Q. Leslie
Complement's participation in acquired immunity
J. Leukoc. Biol., August 1, 2002; 72(2): 249 - 261.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Yin, L. Ma, A. Varghese, J. Shen, and A. S.-F. Chong
Intact Active Bone Transplantation Synergizes with Anti-CD40 Ligand Therapy to Induce B Cell Tolerance
J. Immunol., May 15, 2002; 168(10): 5352 - 5358.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
H. Wardemann, T. Boehm, N. Dear, and R. Carsetti
B-1a B Cells that Link the Innate and Adaptive Immune Responses Are Lacking in the Absence of the Spleen
J. Exp. Med., March 18, 2002; 195(6): 771 - 780.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
R. Ceredig
The ontogeny of B cells in the thymus of normal, CD3{varepsilon} knockout (KO), RAG-2 KO and IL-7 transgenic mice
Int. Immunol., January 1, 2002; 14(1): 87 - 99.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Borrero and S. H. Clarke
Low-Affinity Anti-Smith Antigen B Cells Are Regulated by Anergy as Opposed to Developmental Arrest or Differentiation to B-1
J. Immunol., January 1, 2002; 168(1): 13 - 21.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
P. HASLER and M. ZOUALI
B cell receptor signaling and autoimmunity
FASEB J, October 1, 2001; 15(12): 2085 - 2098.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
P Youinou and P M Lydyard
CD5/ B cells in nonorgan-specific autoimmune diseases: a fresh look
Lupus, August 1, 2001; 10(8): 523 - 525.
[PDF]


Home page
J. Immunol.Home page
S. Santulli-Marotto, Y. Qian, S. Ferguson, and S. H. Clarke
Anti-Sm B Cell Differentiation in Ig Transgenic MRL/Mp-lpr/lpr Mice: Altered Differentiation and an Accelerated Response
J. Immunol., April 15, 2001; 166(8): 5292 - 5299.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. H. Wortis and R. Berland
Cutting Edge Commentary: Origins of B-1 Cells
J. Immunol., February 15, 2001; 166(4): 2163 - 2166.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qian, Y.
Right arrow Articles by Clarke, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qian, Y.
Right arrow Articles by Clarke, S. H.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
Medline Plus Health Information
*Lupus


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS